PRESS RELEASE published on 11/01/2024 at 18:18, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
BRIEF published on 10/24/2024 at 21:13, 1 year 3 months ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
PRESS RELEASE published on 10/24/2024 at 21:08, 1 year 3 months ago Inside Information / News release on accounts, results GenSight Biologics reports €3.4 million cash position as of September 30, 2024, updates on LUMEVOQ® drug product status, and financial discussions for future funding Cash Position Financial Update GenSight Biologics LUMEVOQ AAC Resumption
BRIEF published on 10/17/2024 at 07:35, 1 year 3 months ago GenSight Biologics Presents LUMEVOQ® Data at AAO 2024 Gene Therapy GenSight Biologics LUMEVOQ® LHON AAO 2024
PRESS RELEASE published on 10/17/2024 at 07:30, 1 year 3 months ago Inside Information / Other news releases GenSight Biologics to present scientific updates on LUMEVOQ® gene therapy at AAO 2024, including real-world experience and long-term outcomes for LHON patients Gene Therapy GenSight Biologics LHON LUMEVOQ AAO 2024
PRESS RELEASE published on 09/27/2024 at 11:24, 1 year 4 months ago HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF published on 09/23/2024 at 19:41, 1 year 4 months ago GenSight Biologics Reports Interim Financial Results for H1 2024 Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
PRESS RELEASE published on 09/23/2024 at 19:36, 1 year 4 months ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2024, highlighting optimized cash management, extension of cash runway, and upcoming LUMEVOQ® drug product release Cash Management GenSight Biologics Interim Financial Results LUMEVOQ® Drug Product Release
BRIEF published on 09/17/2024 at 14:45, 1 year 4 months ago Goldman Sachs sells its GENSIGHT BIOLOGICS SA shares Euronext Paris Goldman Sachs Crossing Thresholds Transfer Of Shares GenSight Biologics
BRIEF published on 07/23/2024 at 07:35, 1 year 6 months ago GenSight Biologics Reports Financial Position and Business Progress Gene Therapy Financial Update GenSight Biologics LUMEVOQ Early Access Program
Published on 01/29/2026 at 18:45, 3 hours 18 minutes ago Silver Spruce Appoints Vice-President of Exploration
Published on 01/29/2026 at 18:00, 4 hours 3 minutes ago PPX Mining Announces Grant of Restricted Share Units and Deferred Share Units
Published on 01/29/2026 at 17:00, 5 hours 3 minutes ago Sparta Reports on Delay in Filing Annual Financial Statements
Published on 01/29/2026 at 14:30, 7 hours 33 minutes ago Innodata Selected by Palantir to Accelerate Advanced Initiatives in AI-Powered Rodeo Modernization
Published on 01/29/2026 at 14:00, 8 hours 3 minutes ago Horizon Aircraft Partners with RAMPF to Manufacture the Fuselage for its Aircraft
Published on 01/29/2026 at 21:02, 1 hour ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/29/2026 at 20:59, 1 hour 3 minutes ago Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited
Published on 01/29/2026 at 20:57, 1 hour 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 01/29/2026 at 18:00, 4 hours 3 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 4 hours 18 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 4 hours 18 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 10:07, 11 hours 55 minutes ago Deezer confirms demonetization of up to 85% of AI-music streams due to fraud and moves to sell AI-detection tech
